Skip to main content

Table 3 Influence of anxiety on RA disease activity, pain and fatigue over 12 months

From: Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial

  

Crude

Adjusteda

β (95%CI)

p value

β (95%CI)

p value

Average scores (0, 6 and 12 months)

 DAS28-ESR

None

Reference

 

Reference

 

Moderate

0.19 (−0.04, 0.42)

0.097

0.14 (−0.15, 0.42)

0.340

Severe

0.34 (0.11, 0.57)

0.003

0.32 (−0.03, 0.66)

0.071

 Pain

None

Reference

 

Reference

 

Moderate

9.05 (4.01, 14.09)

<0.001

3.44 (−2.76, 9.63)

0.277

Severe

15.03 (9.60, 20.47)

<0.001

9.60 (2.30, 16.90)

0.010

 Fatigue

None

Reference

 

Reference

 

Moderate

15.15 (9.62, 20.68)

<0.001

0.22 (−6.56, 7.00)

0.949

Severe

21.42 (15.08, 27.76)

<0.001

3.12 (−4.39, 10.62)

0.415

12-month outcomes

  

Crude

Odds ratio (95%CI)

p value

Adjusteda

Odds ratio (95%CI)

p value

 Remission DAS28-ESR (<2.6)

None

Reference

 

Reference

 

Moderate

0.74 (0.29, 1.89)

0.528

0.72 (0.25, 2.10)

0.549

Severe

0.79 (0.28, 2.20)

0.647

0.98 (0.33, 2.92)

0.968

 Change in pain (≥10 units)

None

Reference

 

Reference

 

Moderate

0.51 (0.22, 1.16)

0.110

0.46 (0.19, 1.11)

0.083

Severe

2.43 (0.96, 6.16)

0.061

2.88 (0.98, 7.94)

0.046

 Change in fatigue (≥10 units)

None

Reference

 

Reference

 

Moderate

1.11 (0.51, 2.40)

0.790

1.12 (0.48, 2.62)

0.785

Severe

0.99 (0.41, 2.38)

0.985

1.41 (0.54, 3.69)

0.488

  1. aAdjustment for age, gender, ethnicity, disease duration, NHS region and trial arm; anxiety: none n=183; moderate n=65; severe n=50
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us